Home ENGLISH MAGAZINE Intestinal endoscopy: the global coalition of experts have a "gut feeling"

Intestinal endoscopy: the global coalition of experts have a “gut feeling”

Endoscopic therapy has been explored and used in the management of numerous conditions and situations related to inflammatory bowel diseases (IBD), including strictures, fistulas, postsurgical acute or chronic leaks, colitis-associated cancers and obstructions. The endoscopic therapeutic modalities include balloon dilation, stricturotomy, stent placement, fistulotomy, fistula injection and clipping, sinusotomy and both endoscopic mucosal resection and sub-mucosal dissection. With a better understanding of the disease process and course of IBD, improved long-term impact of medical therapy, and advances in endoscopic technology, researchers foresee interventional IBD becoming an integrated part of the multidisciplinary approach to patients with complex IBD. In recent decades, rapid advances have taken place in medical and surgical therapy for both Crohn’s disease (CD) and ulcerative colitis (UC). For example, the availability and growing use of biologic drugs (monoclonal antibodies) have been shown to result in deep clinical remission beyond improvement of symptoms.

These medical treatments also reduce the risk for adverse events associated with IBD, thereby avoiding hospitalization and surgery for some patients. Additional pharmacologics have been and are being investigated. However, the long-term impact of the appropriate use of these drugs on the natural history of IBD is not clear. In addition, the long-term use of these immunosuppressive agents can be associated with various adverse events, ranging from infections, increased risk for certain cancers up to a paradoxic autoimmune response. Furthermore, a significant number of patients with CD or UC still require surgical intervention for medically refractory disease or disease-associated adverse events such as strictures, fistulas and secondary tumors. The common surgical treatment modalities for CD or ulcerative colitis include bowel resection, strictureplasty, anastomosis, stoma construction, and restorative procto-colectomy with ileal pouch-anal anastomosis.

Although the surgical approach offers an immediate resolution of symptoms and relief of mechanical or neoplastic adverse events, it is often associated with postoperative adverse events and postoperative disease recurrence. Current unmet needs in IBD management include the availability of therapeutic approaches to mechanical adverse events that can reach beyond the limits of pharmacologic agents and are less invasive than surgery. Therapeutic endoscopy can offer a unique bridge between medical and surgical treatments. Endoscopic management of mechanical and neoplastic adverse events may help reduce or postpone the need for surgical resection and help treat postoperative adverse events, if surgery is performed. Currently, four main areas of IBD are amenable to endoscopic treatment: strictures, fistulas or abscesses, colon cancers and IBD surgery-associated adverse events.

According to a new statement from a panel of national and international experts in gastroenterology, inflammatory bowel disease and other areas, therapeutic IBD endoscopy has an expanding role in the treatment of disease and of adverse events from surgery. To meet the growing need for endoscopic treatment in complex IBD, a panel of national and international experts in gastroenterology, IBD, advanced endoscopy, GI radiology, GI pathology, GI education, and colorectal surgery voluntarily formed a subspecialty group in 2018, the Global Interventional IBD Group, to coordinate clinical, educational, and investigational activities. This self-appointed group includes a mixture of IBD specialists with expertise in endoscopy and endoscopists dedicated to IBD. In addition, the group also consists of IBD pathologists and IBD specialists with expertise in abdominal imaging. They mean to continue and expand this work.

The report from the panel, “Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement for the Global Interventional IBD Group”, is published in the latest issue of Gastrointestinal Endoscopy journal.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Shen B et al. Gastrointest Endosc. 2019 Feb; 89(2):215.

Plevris N et al., Lees CW. J Crohns Colitis 2019 Feb 14. 

Wan J, Wang X, Yang Z, Wu K. J Dig Dis. 2019 Feb 12. 

Lan N, Stocchi L et al. Gastrointest Endosc. 2019 Jan 30. 

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web salutesicilia.com e medicomunicare.it

ARTICOLI PIU' LETTI